Literature DB >> 20922465

Reciprocal regulation of 11β-hydroxysteroid dehydrogenase 1 and glucocorticoid receptor expression by dexamethasone inhibits human coronary artery smooth muscle cell proliferation in vitro.

George Michas1, Marcel Liberman, Kristian C Becker, Diane E Handy, Joseph Loscalzo, Jane A Leopold.   

Abstract

The actions of glucocorticoids are mediated, in part, by 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), which amplifies their effects at the pre-receptor level by converting cortisone to cortisol. Glucocorticoids, such as dexamethasone, inhibit vascular smooth muscle cell proliferation; however, the role of 11β-HSD1 in this response remains unknown. Accordingly, we treated human coronary artery smooth muscle cells (HCSMC) with dexamethasone (10(-9)-10(-6) mol/l) and found that after 72 h dexamethasone increased 11β-HSD1 expression (14.16 ± 1.6-fold, P < 0.001) and activity (6.21 ± 1.2-fold, P < 0.001) in a dose- and time-dependent manner, which was dependent upon glucocorticoid receptor (GR) activation and C/EBPβ and C/EBPδ signaling. As glucocorticoids are known to negatively regulate GR expression, we examined the effect of decreasing 11β-HSD1 expression on GR expression. In HCSMC transfected with 11β-HSD1 siRNA, GR expression was increased; this effect was associated with protein kinase A activation and CREB phosphorylation. To examine the role of 11β-HSD1 in HCSMC proliferation, we decreased 11β-HSD1 expression and stimulated cells with platelet-derived growth factor (PDGF) (10 ng/ml). Decreased 11β-HSD1 expression was associated with increased cell proliferation in the absence of PDGF compared to scrambled control-transfected cells (236.10 ± 13.11%, n = 4, P < 0.001) and this effect was augmented by PDGF. Furthermore, the inhibitory effect of dexamethasone on cellular proliferation was abrogated in 11β-HSD1 siRNA-transfected HCSMC. Downregulation of 11β-HSD1 was associated with decreased p27(kip1) expression and increased phosphorylated retinoblastoma protein, consistent with a proliferative response. These findings suggest that 11β-HSD1 plays a role in the effects of glucocorticoids on vascular smooth muscle cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922465      PMCID: PMC2996480          DOI: 10.1007/s11010-010-0592-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

Review 1.  Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function.

Authors:  P W F Hadoke; L Macdonald; J J Logie; G R Small; A R Dover; B R Walker
Journal:  Cell Mol Life Sci       Date:  2006-03       Impact factor: 9.261

2.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

3.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

Authors:  Francesco Versaci; Achille Gaspardone; Fabrizio Tomai; Flavio Ribichini; Paolo Russo; Igino Proietti; Anna Silvia Ghini; Valeria Ferrero; Luigi Chiariello; Pier Agostino Gioffrè; Francesco Romeo; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

4.  CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11beta-hydroxysteroid dehydrogenase encoding gene in adipose cells.

Authors:  Johann Gout; Julien Tirard; Chantal Thévenon; Jean-Paul Riou; Martine Bégeot; Danielle Naville
Journal:  Biochimie       Date:  2006-07-05       Impact factor: 4.079

5.  Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis.

Authors:  Gary R Small; Patrick W F Hadoke; Isam Sharif; Anna R Dover; Danielle Armour; Christopher J Kenyon; Gillian A Gray; Brian R Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

6.  Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries.

Authors:  Nuno M M Pires; Abbey Schepers; Barend L van der Hoeven; Margreet R de Vries; Lianne S M Boesten; J Wouter Jukema; Paul H A Quax
Journal:  Cardiovasc Res       Date:  2005-07-15       Impact factor: 10.787

Review 7.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

8.  Glucocorticoid-related signaling effects in vascular smooth muscle cells.

Authors:  Gergö A Molnar; Carsten Lindschau; Galyna Dubrovska; Peter R Mertens; Torsten Kirsch; Marcus Quinkler; Maik Gollasch; Stefanie Wresche; Friedrich C Luft; Dominik N Muller; Anette Fiebeler
Journal:  Hypertension       Date:  2008-03-17       Impact factor: 10.190

9.  A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.

Authors:  Charlotte Bruley; Val Lyons; Alan G F Worsley; Margaret D Wilde; Gretchen D Darlington; Nik M Morton; Jonathan R Seckl; Karen E Chapman
Journal:  Endocrinology       Date:  2006-03-16       Impact factor: 4.736

10.  Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta.

Authors:  Shuji Sai; Cristina L Esteves; Val Kelly; Zoi Michailidou; Karen Anderson; Anthony P Coll; Yuichi Nakagawa; Takehiko Ohzeki; Jonathan R Seckl; Karen E Chapman
Journal:  Mol Endocrinol       Date:  2008-07-10
View more
  1 in total

1.  Striatal miR-183-5p inhibits methamphetamine-induced locomotion by regulating glucocorticoid receptor signaling.

Authors:  Sang-Hoon Song; Won-Jun Jang; Eun Young Jang; Oc-Hee Kim; Haesoo Kim; Taekwon Son; Dong-Young Choi; Sooyeun Lee; Chul-Ho Jeong
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.